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Abstract 
One of the most effective methods to tackle obesity and its related comorbidities is bariatric 
surgery. Polycystic ovary syndrome (PCOS) and endometrial hyperplasia (EH), which are 
associated with increased risk of endometrial carcinoma, have been identified as potentially 
new indications for bariatric surgery. 
PCOS is the most common endocrine disorder in women in the reproductive age and is 
associated with several components of the metabolic syndrome such as obesity, insulin 
resistance and hypertension. EH is a pre-cancerous condition which arises in the presence of 
chronic exposure to estrogen unopposed by progesterone such as both in PCOS and obesity.  
The main bariatric procedures are Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy 
and laparoscopic adjustable gastric banding. These procedures are well established and when 
correctly selected and can safely achieve significant sustainable weight loss and remission of 
obesity-related co-morbidities when performed by experienced bariatric surgeons.  
Studies have shown that bariatric surgery can play an important role in the management of 
patients with PCOS and improve fertility. Similarly, bariatric surgery has a positive effect on 
endometrial hyperplasia, making surgically induced weight loss a potentially attractive option 
for endometrial cancer prevention and treatment. 
Obesity has an adverse impact on spontaneous pregnancy, assisted reproduction methods  and 
feto-maternal outcomes. After bariatric surgery obese women with subfertility can achieve 
spontaneous pregnancy. However, while bariatric surgery reduces the risk of pre-eclampsia and 
gestational diabetes, there is an increased risk of small for gestational age and possible 
increased risk of stillborn or neonatal death.      
In this article we will review the evidence regarding the use of bariatric surgery as a treatment 
modality in patients with PCOS and EH.  We also provide an overview of the common bariatric 
procedures. 
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Introduction 
Obesity is a global epidemic  with over 2.1 billion people worldwide now regarded as 
overweight or obese [1], which is likely to increase despite various steps that have been taken 
to address this problem such as public education, instituting sugar tax schemes or reducing the 
calorific content in foods [2-4].  One of the more recent methods to treat obesity is bariatric 
surgery and current evidence support that it is an effective treatment that results in sustainable 
reductions in weight and in the risks associated with morbid obesity and the related co-
morbidities [5]. In 2013 the registered bariatric procedures worldwide have reached a historic 
high number of 470,000 [6]. With improvement in all outcomes, the eligibility criteria for 
bariatric surgery continue to expand [7-9]. Moreover, new potential indications are emerging 
such as idiopathic intracranial hypertension, non-alcoholic fatty liver disease, chronic kidney 
disease, polycystic ovary syndrome (PCOS) and endometrial hyperplasia (EH) [10-12][13-14].  
PCOS is the most common endocrinopathy of women of reproductive age that is associated 
with insulin resistance, hyperandrogenism, adverse cardiovascular risk factors and subferility. 
Identification and management of PCOS constitute a major burden for the healthcare system 
[15]. Endometrial hyperplasia is a relatively common condition that affects women of all age 
groups. It relates to excessive cellular proliferation leading to increased volume of the 
endometrial tissue [16]. EH is diagnosed three times more commonly than endometrial cancer, 
and can progress to cancer if left untreated. Without intervention, the risk of progression to 
carcinoma (EC) is less than 1% for women with simple hyperplasia, 3% for complex nonatypical 
hyperplasia, and up to 29% for women with atypical complex hyperplasia [17]. World Health 
Organisation guidelines in 2014 have re-classified EH by categorizing it as hyperplasia without 
atypia and hyperplasia with atypia [18].   
A recent systematic review showed that the risk of EC was three times higher in women with 
PCOS compared to women without the disease. The risk is even higher, up to three folds in 
obese women, and obesity is a predominant feature in PCOS. Management strategies to reduce 
the risk of EC in women with PCOS are therefore vital [16].  
Polycystic Ovary Syndrome 
PCOS can affect up to 10% in women of reproductive age [19]. PCOS is a heterogeneous 
disorder in which the principal features are androgen excess (clinically or biochemically), 
ovulatory dysfunction, and polycystic ovaries [13,15]. 
The pathogenesis of PCOS remains uncertain and likely to be multifactorial including 
interactions between genetic and environmental factors such as fetal exposure to androgens, 
obesity and sedentary lifestyle. These can lead to increased GnRH pulsatile secretion and 
hyperinsulinaemia/insulin resistance, both of which result in increased adrenal and ovarian 
androgen secretion. The overall effect is an increased level of free androgens (worsened by 
reducing SHBG) resulting in the clinical features of hirsutism, anovulation and infertility (by 
arresting follicular development) [15]. 
Anovulation results in subfertility and decreased progesterone release result in unopposed 
oestrogen effects causing breakthrough bleeds and increased risk of endometrial hyperplasia, 
which can progress to endometrial cancer (2.7-fold risk increase) [21].  
PCOS in both lean and obese individuals is independently associated with impaired glucose 
tolerance, insulin resistance, metabolic syndrome, type 2 diabetes mellitus, hypertension, 
increased risk of cardiovascular disease, deranged lipid profile, sleep apnoea and obesity 
[7,13,20,22-23]. Obesity and PCOS additively contribute to the evolution of metabolic 
syndrome. The similarity in the background and mechanism has led to the opinion that PCOS 
constitutes a female type of metabolic syndrome (syndrome XX) [24]. Obesity is very common 
in PCOS with almost 60% of affected women being obese [25]. This obesity is predominantly 
central, contributing further to the establishment of metabolic syndrome even in very young 
individuals [22].  Hyperinsulinaemia plays a cardinal role in the pathophysiology of both PCOS 
and metabolic syndrome with hyperandrogenaemia.  Both lean and obese women with PCOS 
have increased circulating insulin levels relative to those of serum glucose compared with 
healthy lean and obese women [26]. Such a finding strongly suggests a certain degree of 
hepatic insulin resistance irrespective of obesity. Of note is that lean PCOS females present only 
hepatic insulin resistance while obese affected individuals present global insulin resistance [15]. 
Hence, there is a significant metabolic heterogeneity in women with PCOS strongly influenced 
by obesity. Forty percent of such women will develop diabetes by the age of 50. This is not 
always dependent on BMI. The development of diabetes is not only attributed to peripheral 
insulin resistance but also to insufficient β-cell response to meals [27]. 
The relationship between PCOS and obesity is multifactorial and bi-directional. PCOS can 
exacerbate obesity and obesity can exacerbate PCOS in a vicious cycle pattern [20]. Additionally, 
PCOS clearly negatively affects the main components of the metabolic syndrome which 
constitute the established indications for bariatric surgery (such as type 2 diabetes, 
hypertension or hyperlipidaemia) [13,15]. In this context, PCOS represents an indirect target of 
bariatric interventions. 
The current treatment strategies for PCOS include mainly lifestyle modifications along with 
insulin sensitizers (predominantly metformin) and other symptomatic treatments (such as oral 
contraceptives and progestins, anti-androgens). As obesity plays an important role in the 
pathogenesis of PCOS, bariatric surgery is being increasingly utilized as a treatment strategy 
[15].   
Endometrial hyperplasia 
Endometrial hyperplasia (EH) is a pre-cancerous, non-physiological, non-invasive proliferation 
of the endometrium that results in increased volume of endometrial tissue with alterations of 
glandular architecture (shape and size) and endometrial gland to stroma ratio of greater than 
1:1 [28]. The majority of cases of EH arise in the presence of chronic exposure to oestrogen 
unopposed by progesterone such as in PCOS and obesity. EH is classified according to the WHO 
classification system (Table 1). 
 
The main risk factor for endometrial hyperplasia is increased unopposed oestrogen levels. 
Consequently any related condition constitutes a risk factor.  
Obesity and EH 
Obesity leads to high oestrogen relative to progesterone levels by various mechanisms:  
1.  increased peripheral conversion of androstenedione to oestrone within adipose stores 
2. decreased circulating sex hormone-binding globulins, and 
3. increased rates of anovulation [29-30].  
Women with a BMI≥40 kg/m2 are at a 13-fold increased risk of EH with atypia and a 23-fold 
increased risk of EH without atypia, chronic anovulation and PCOS [30]. Furthermore, BMI ≥35 
kg/m2 is strongly associated with failure to regress and relapse of complex hyperplasia treated 
with levonorgestrel-releasing (progestogen) intrauterine system [17]. Interestingly PCOS 
associated abnormalities such as obesity, nulliparity, infertility and diabetes can all act as risk 
factors independently as well as in the context of the syndrome [29].  
Oestrogen-only hormone therapy and selective oestrogen receptor modulators (tamoxifen but 
not raloxifen) are also strongly associated with EH [30-31]. Lynch syndrome (hereditary non-
polyposis colorectal cancer, also related with other cancers including endometrial, ovarian, 
gastric, small intestine, hepatobiliary tract, upper urinary tract, brain, and skin) have also been 
indirectly related to endometrial hyperplasia due to relative findings from screening studies for 
endometrial cancer. 
Current treatment strategies for EH 
The risk reduction strategies include the addition of progestogens to post-menopausal 
oestrogen replacement regimes, the treatment of PCOS-related anovulation and the aggressive 
management of obesity, diabetes and metabolic syndrome [23]. The mainstay recommendation 
for the treatment of EH without atypia is with the levonorgestrel releasing intrauterine system 
(LNG-IUS) [32, 33, 17].  An RCOG guideline now provides a comprehensive management plan 
for women with EH and bariatric surgery is recommended for reducing the risk of EH without 
atypia (Evidence level 2-) [34]. 
Bariatric surgery, PCOS and EH 
In patients with PCOS and/or EH, addressing obesity, when present, can have significant 
benefits to the patients metabolic health. 
The most successful treatment that results in sustained long term weight loss is bariatric 
surgery as the benefits obtained from dietary and lifestyle interventions are usually not 
sustained over the long-term [40-41]. Bariatric surgery results in greater improvement in weight 
loss outcomes and obesity-related comorbidities when compared with nonsurgical 
interventions, regardless of the type of surgical procedure used [42-43]. The most well 
recognized obesity-related co-morbidities are: Type 2 diabetes mellitus (DM2), hypertension, 
sleep apnoea, dyslipidaemia, metabolic syndrome and osteoarthritis. More morbid conditions 
are proven to be weight-related and consequently are added to the potential targets of 
bariatric surgery. Characteristic examples are PCOS and EH. Bariatric surgery also results in 
significant improvement on quality of life parameters [44]. 
Current bariatric procedures 
Many different surgical options of a variety of magnitude are currently available. They can be 
broadly divided into restrictive and malabsorptive procedures. However with increasing 
evidence for the mechanism of action, these boundaries are getting increasingly blurred. 
Restrictive procedures work mainly by mechanically reducing portion sizes i.e., by creating 
gastric inlet restriction. Malabsorptive procedures induce their effect by reducing the amount 
of active bowel, by creating a by-passing effect. It is now felt that the mechanisms behind 
weight loss following surgery are multifactorial including changes in the gut hormones 
(increased GLP-1 and PYY and reduced ghrelin), changes to energy expenditure, reduction in 
food intake and changes in food choices favouring less calorie dense food, possibly due to 
changes in taste and food perception and changes to gut microbial and bile salts metabolism 
[40-43].   
Roux-en-Y gastric bypass (GBP): GBP is considered nowadays to be the gold-standard and most 
commonly performed bariatric procedure worldwide [6]. It offers a sustainable excess weight 
loss (EWL) of 60-65% achieved in the first 18-24 months after the procedure.   
GBP procedure can be divided in 2 steps (Figure 1): 
- The creation of a small proximal gastric pouch (volume <50mls) with the use of surgical 
staplers excluding the distal stomach, duodenum and proximal jejunum from the 
passage of food 
- The reconstruction of the continuity of the GI track with a Roux-en-Y loop consisting of 2 
anastomoses (jejuno-jejunal and gastro-jejunal) and thus defining an alimentary limp 
(100-150cm from the gastro-jejunal to the jejuno-jejunal anastomosis), a biliopancreatic 
limp (50-100cm from the ligament of Treitz to the jejuno-jejunal anastomosis) and a 
common limp (the rest of the small bowel from the jejuno-jejunal anastomosis to the 
ileocaecal valve). 
Sleeve Gastrectomy (SG): SG although more recently introduced, has gained significant 
attention and is becoming widely accepted as a single stage procedure [43]. It has become the 
most commonly performed bariatric procedure in Europe and the second popular worldwide, 
due to its technical simplicity and relatively low complication rate [6]. Excess weight loss is 
sustained to 60% even in the long term follow up (5 years) [45-46].  
Sleeve gastrectomy is performed with the use of surgical staplers and by longitudinally 
transecting the stomach, sparing approximately 5cm of antrum and up to the Angle of His (to 
the left of the gastro-oesophageal junction), leaving a tubular gastric remnant of 100-150mls 
(Figure 2). 
 
 
Adjustable gastric band (AGB): AGB has been a well-established method for many years mainly 
benefiting from a low peri-operative morbidity and mortality. It accounts for 10% of bariatric 
operations worldwide. Of note is that initial weight loss is slow and mainly depends on the 
aggressiveness of adjustments (centre-dependent), but generally is at the level of 45-50% of 
excess weight and has proven sustainable even 15 years after the procedure [36,47-48]. 
A silicon band is implanted around/just below the gastro-oesophageal junction and is 
connected to a subcutaneous port for access and adjustment of the chamber of the band thus 
adjustment of the inner diameter (Figure 3). 
Mortality and morbidity following bariatric surgery 
Bariatric surgery gained popularity as it was associated with favorable figures of peri-operative 
complications and mortality. A meta-analysis from Buchwald reported a 30-day mortality rate 
of 0.1% for combined AGB and gastroplasty and 0.5% for GBP, despite including open bariatric 
operations [36]. More recent data in the laparoscopic era report very low mortality figures 
ranging from 0.05, 0.11 and 0.14% for AGB, SG and GBP, respectively [49]. 
Immediate post-operative morbidity is also low and mainly reflects the risk of staple line and 
anastomotic leak after SG and GBP (approximately 1%) and bleeding (approximately 1%). 
Hospital stay is low and ranges usually from 0 (day-case gastric bands) to 2 days (stapled 
procedures).    
Weight-loss outcomes after bariatric surgery 
A meta-analysis for weight-loss was first published by Buchwald in 2004 and included 22,000 
patients [36]. It confirmed an excess weight loss between 48 and 70% over 2 years for the 4 
procedures analysed. Since then a large number of meta-analyses have been published with 
comparable or better outcomes. The most frequently index used to assess weight loss is 
percentage excess weight loss (%EWL) which is provided by the equation [50]:  
%EWL = (preoperative weight – current weight)x100/(preoperative weight – ideal weight) 
Co-morbidity resolution after bariatric surgery 
Bariatric surgery has been shown to be superior to medical therapy in achieving glycaemic 
control targets and diabetes remission in patients with Type 2 diabetes. The remission rate of 
Type 2 diabetes varies between studies due to variation in the definition of remission, which is 
much stricter in recent studies, the diabetes duration, the beta cell reserve at the time of 
surgery and the follow up after surgery. Overall, remission rates decrease over longer follow up 
and with longer diabetes duration and mire advanced beta cell failure.  In addition diabetes 
remission rates are different for the 3 main procedures and reveal the escalating complexity of 
their physiology. In general bariatric surgery is a fast and efficient treatment for diabetes. This 
was highlighted 20 years ago by Pories et al who reported diabetes and glucose tolerance 
impairment resolution rates of 83% and 99% respectively, with follow up of up to 14 years after 
GBP [51]. Buchwald’s meta-analysis reported a remission rate that ranged from 48% for AGB, to 
84% for GBP and to 98% for BPD [36]. This study did not include SG data. The above results 
have been confirmed by more recent studies that also included SG which offered a remission 
rate of 66-71% [46,52]. The most recent meta-analysis reported remission rate after GBP to be 
66% after applying stricter criteria and with a follow up 2-5years [53].              
Similarly, bariatric surgery has significant impact on other obesity-related comorbidities. 
Hypertension remission rates are approximately 20-43, 40-70 and 45-68% for AGB, SG and GBP 
respectively. Sleep apnoea remission rates are 29-68, 57-87 and 66-80% and dyslipidaemia 
remission rates are 27-59, 40-62 and 63-97%, respectively [36,46,52]. 
Equally important is the positive effect of bariatric surgery on health related quality of life. An 
increasing number of studies indicate that quality of life, measured by both generic and 
obesity-specific instruments, markedly improves after a bariatric intervention, although it might 
not reach this of non-obese population [54]. 
Although the above comorbidities are almost consistently reported in every bariatric 
publication other significant obesity-related conditions, such as PCOS, EH and infertility, have 
attracted less attention.  
The impact of bariatric surgery in patients with PCOS and/or EH 
PCOS: Life style interventions remain the first-line treatment in women with PCOS, but bariatric 
surgery is increasingly recognized as a possible treatment for women with PCOS and was 
recently recommended by RCOG as a possible treatment option in women who fail to achieve 
significant weight loss with lifestyle interventions and a BMI above 40 kg/m2 (or 35 kg/m2 in the 
presence of other obesity comorbidities).  
 Meta-analysis of randomized and non-randomized trials and case-series found only 13 studies. 
The studies included 2130 female patients, with 10 out of 13 of the studies including <100 
participants. The mean ages and BMI in the studies included in the meta-analysis ranged 16-44 
years (weighted mean 30.8 years) and 44-52 kg/m2 (weighted mean 46.3 kg/m2) respectively, 
with a weighted mean of 14 months follow up duration. Overall bariatric surgery resulted in 
reductions in PCOS (OR 0.27, 95% CI 0.14-0.52; p<0.001), hirsutism (OR 0.12, 95% CI 0.04-0.36; 
p<0.001), menstrual irregularities (OR 0.07, 95% CI 0.03-0.21; p <0.001) and infertility (OR 0.35, 
95%CI 0.19-0.65; p<0.001) [13]. While, the meta-analysis concluded that bariatric surgery 
effectively attenuated PCOS and its clinical symptomatology, including subfertility, in severely 
obese women the lack of RCTs and the heterogeneity of PCOS definitions amongst studies are 
major limitations. In another study of 20 women with obesity and PCOS who received GBP and were 
followed up for about 4 years, menstruation was corrected in 82%, and hirsutism resolved in 29% 
[55]. Of the 10 patients who did not conceive before surgery, 6 patients had become pregnant 
within 3 years of surgery [55]. 
The impact of bariatric surgery in women with PCOS seems to be mediated by improvements in 
insulin resistance and androgen levels after surgery [13]. However, improvements in menstrual 
cycling and hirsutism did not correlate with the weight loss after surgery, suggesting a role for 
weight-independent mechanisms in the impact of bariatric surgery in women with PCOS [56]. 
The changes in weight loss after GBP are similar in women with and without PCOS. 
However, weight-loss via pharmacotherapy and/or life style intervention is also beneficial in 
women with PCOS. In a study of 59 obese adolescent females with PCOS aged 12–18 years, who 
underwent 1 year of lifestyle intervention (nutrition education, exercise training, and 
behavioural therapy), in the 26 girls who lost weight (−3.9kg/m2), testosterone concentrations 
decreased significantly by a mean of 0.3nmol/litre and SHBG concentrations increased 
significantly by a mean of +8ng/ml compared to the subjects with increasing weight. 
Furthermore, the prevalence of amenorrhea and oligoamenorrhea was reduced by 42% and 
19%, respectively [57]. A recent meta-analysis suggested that orlistat-induced weight loss in 
overweight and obese women with PCOS can reduce testosterone, insulin resistance markers 
and improve lipid profile. But due to the small sample size the meta-analysis was inconclusive 
on whether orlistat is advantageous over the established second line treatment with metformin 
[58].  
It is not possible to be certain whether bariatric surgery is superior to lifestyle interventions or 
weight loss pharmacotherapy in women with obesity and PCOS due to the lack of randomized 
controlled trials. However, bariatric surgery has been proven to be superior to other methods 
of weight loss in patients with BMI ≥35 kg/m2 in regards to the durability of the surgical weight 
loss, the impact on cardiovascular disease factors, the impact on glucose metabolism and 
quality of life.    
EH:  EH can occur in 7-10% of patients with morbid obesity [30,59-62]. This represents a 23-fold 
increase of the risk of EH in morbidly obese females [28]. It has been shown that bariatric 
surgery has a positive effect on endometrial histological changes and can ameliorate the risk of 
endometrial pathology [30,59,62].  In a meta-analysis of 3 studies involving 890,110 
participants, bariatric surgery lowered the risk of endometrial cancer compared with controls 
(RR= 0.40, 95% CI 0.20 - 0.79) [63]. Surgically induced weight loss represents a potentially 
attractive option for EC prevention and treatments [61], but RCTs are needed. Unfortunately 
there are no well-designed studies to report the impact of medical weight management on EH 
and even more to compare surgical versus medical treatment. It has been suggested though 
that metformin can act as a preventive measure of progression of EH as it is a potent inhibitor 
of endometrial cell proliferation by reducing the metabolic syndrome and lowering insulin and 
testosterone levels in postmenopausal overweight women [64]. 
Infertility: Increased BMI is associated with hyperleptinaemia, insulin resistance and 
hyperandrogenism all of which contribute to chronic anovulation and subfertility [65]. 
Abnormal LH pulsatility might also lead to abnormal oocyte recruitment, poor oocyte quality 
and altered endometrial development which could affect the function of the corpus luteum 
[66]. In addition to its impact on ovulation, obesity affects endometrial development, uterine 
receptivity, implantation, and miscarriage [67]. Furthermore, obesity is associated with 
increased risk for the mother (miscarriage, gestational diabetes, hypertension, pre-eclampsia, 
dysfunctional labour and caesarean section) and for the neonate (congenital malformations, 
macrosomia, and admission to a neonatal care unit). The risk of stillbirth is also strongly related 
to maternal BMI. 
According to a meta-analysis of 13 case-series including 2130 PCOS patients, bariatric surgery 
lowers the risk of infertility (OR 0.35, 95%CI 0.19-0.65; p<0.001) [13].  In a different a meta-
analysis of 8 studies (589 women, age 31-45 years, baseline BMI 40.9-50 kg/m2), the weighted 
mean incidence for successful pregnancy after bariatric intervention was 0.580 (95% CI 0.539-
0.621, p < 0.001) which is not very far for the expected incidence for the “healthy population”, 
in which 1 in 4 couples is expected to be affected by infertility [66]. 
Obesity is associated with significant adverse outcomes to the mother and newborn.  As a 
result the British Fertility Society policy and practice guidelines recommend deferring any 
treatment until a woman’s BMI is <35 kg/m2, and recommending that BMI <30 kg/m2 is 
preferable [67].  
For the neonate there is strong evidence that after surgically induced weight loss the risk for 
excessive fetal growth is reduced while prematurity and small-for-gestational-age infants is 
more frequently expected [65,68]. Interestingly a sub-group analysis showed no increased 
prematurity risk after gastric band suggesting a potential correlation of prematurity and 
micronutrients malabsorption following other bariatric interventions [68].  
Assisted reproduction: Ovarian stimulation is less likely to be successful with clomifene in 
obese patients and higher doses of gonadotrophins were required [65]. Despite that more 
recent studies have shown that oocyte numbers retrieved and pregnancy rates were not worse 
in comparison to normal BMI counterparts [65]. Similarly in intrauterine insemination when 
medication dosages were adjusted to overcome the weight-effect, the success of the treatment 
cycle was comparable to that of normal-weight women [65]. On the other hand for IVF 
methods obese patients had a 65% lower odds of having a live birth (LB) following their first IVF 
cycle comparing to patients with a BMI<30kg/m2 [69]. Data from the Society for Assisted 
Reproduction Technology (SART) show that the odds of failing to achieve live birth was 18-48% 
higher for overweight and obese women (depending on the BMI) and significantly increased 
adjusted odds for fetal loss and stillbirth [70]. Thus, overweight and obese women undergoing 
ART appear to be disadvantaged with respect to the dosage and duration required for ovarian 
stimulation, embryo implantation, pregnancy and LB rates as well as in the frequency of 
miscarriage and recurrent early pregnancy loss. Specific data on IVF after bariatric surgery are 
limited and quite preliminary but it seems that the bariatric intervention reduces treatment 
costs without affecting oocyte or embryo quality [71].   
Conclusion 
Bariatric surgery results in significant and sustained weight loss and improvements in obesity-
related comorbidities. Non-randomised studies suggest that bariatric surgery could play an 
important role in the management of patients with PCOS and/or endometrial hyperplasia but 
randomized controlled trials are needed. 
Bariatric surgery is an expanding field that is offering sustainable results both for weight loss 
and remission of co-morbidities. As new indications for bariatric surgery emerge and more 
diseases are more closely linked to the epidemic of obesity, the wider acceptance of weight-loss 
surgery as an addition to the treatment options will assist the optimization of the multi-
modality management of conditions such as PCOS and EH which affect a large number of young 
population of reproductive age.    
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Table 1: Endometrial Hyperplasia classification 
 
Classifying 
system 
Type 
WHO (1994) Simple 
hyperplasia 
Complex 
hyperplasia 
Simple 
hyperplasia with 
atypia 
Complex atypical 
hyperplasia 
Revised WHO 
(2003) 
Proliferative 
endometrium 
Simple 
hyperplasia 
Complex 
hyperplasia 
Complex atypical 
hyperplasia 
WHO (2014) Endometrial hyperplasia without 
atypia 
 
Endometrial hyperplasia with atypia 
 
 
